Table 5.
Summary of the case report findings on COVID-19, 2020.
| Variable | n | %* |
|---|---|---|
| Age (months) (mean, SD) (n = 53) | 44.4, 48.8 | 44.8 |
| Sex (male/female) (n = 52) | 33 | 64.5 |
| Clinical features | ||
| Fever | 39/53 | 73.4 |
| Cough | 23/53 | 43.4 |
| Shortness of breath/dyspnea | 8/53 | 15.1 |
| Sore throat | 2/53 | 3.8 |
| Diarrhea | 13/53 | 24.5 |
| Nasal symptoms | 14/53 | 26.4 |
| Myalgia or fatigue | 11/53 | 20.8 |
| Sputum production | 6/53 | 11.3 |
| Nausea or vomiting | 11/53 | 20.8 |
| No symptoms | 5/53 | 9.4 |
| Laboratory findings | ||
| Normal | 8/47 | 17.0 |
| Leukopenia | 6/47 | 12.8 |
| Leukocytosis | 7/47 | 14.9 |
| Lymphopenia | 6/47 | 12.8 |
| High AST | 6/47 | 12.8 |
| High ALT | 2/47 | 4.3 |
| High LDH | 8/47 | 17.0 |
| High C-reactive protein | 16/47 | 34.0 |
| High procalcitonin | 10/47 | 21.3 |
| High creatinine | 2/47 | 4.3 |
| High creatine kinase | 6/47 | 12.8 |
| High CK-MB | 9/47 | 19.1 |
| High bilirubin | 4/47 | 8.5 |
| Decreased albumin | 2/47 | 4.3 |
| Images | ||
| Normal | 11/45 | 24.4 |
| Abnormal | 34/45 | 75.6 |
| Unilateral pneumonia | 10/45 | 22.2 |
| Bilateral pneumonia | 19/45 | 42.2 |
| Ground-glass opacity | 12/45 | 26.7 |
| Pulmonary consolidation | 9/45 | 20.0 |
| Patchy shadowings | 13/45 | 28.9 |
| Treatment | ||
| Symptomatic treatment | 9/44 | 20.5 |
| Oxygen supply | 7/44 | 15.9 |
| Noninvasive/mechanical ventilation | 4/44 | 9.1 |
| Oseltamivir | 9/44 | 20.5 |
| Ribavirin | 5/44 | 11.4 |
| Lopinavir/litonavir/ribavirin | 4/44 | 9.1 |
| Interferon-alpha | 30/44 | 68.2 |
| Glucocorticoids | 5/44 | 11.4 |
| Immunoglobulin | 7/44 | 15.9 |
| Antibiotics | 18/44 | 40.9 |
| Traditional Chinese medicine | 7/44 | 15.9 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; CK-MB, creatine kinase-MB.
*
Expressed in absolute number and percentage in relation to the total of cases described (n = 53).